Jul. 23, 2014, 5:19 PM
- Sangamo BioSciences (SGMO +6.1%) Q2 results: Total Revenues: $10.4M (+49.8%), Collaboration Agreements: $9.7M (+57.9%); Operating Expenses: $17.4M (+40.6%); Net Loss: ($7.0M) (-28.1%); Quick Assets: $236.7M (+79.6%).
- 2014 Guidance: Revenues: $45M - 50M; Operating expenses: $65M - 70M; Quick Assets: at least $225M by year end.
Jul. 23, 2014, 4:10 PM| 1 Comment
Jul. 22, 2014, 5:35 PM
- AF, AHL, AIZ, ALGT, ALSN, ANGI, ANGO, AVB, AWH, BDN, CA, CAKE, CCI, CHE, CLB, CLGX, CLW, CMRE, CRUS, CSGP, CTXS, EFX, EGHT, ETFC, ETH, FB, FFIV, FLS, FR, FTNT, GGG, GILD, HBI, HWAY, IBKC, ILMN, INFN, KALU, LHO, MAC, MKSI, MSA, NSR, NVEC, NXPI, OHI, OII, ORLY, PLCM, QCOM, QTM, RE, RJF, SFG, SGMO, SKX, SLG, SLM, SUSQ, T, TAL, TCBI, TER, TEX, TILE, TMK, TQNT, TRIP, TSCO, TYL, UMPQ, USTR, VAR, WFT
May. 6, 2014, 4:29 PM
Apr. 3, 2014, 5:38 PM
Mar. 21, 2014, 7:18 AM
- Sangamo BioSciences (SGMO) prices its offering of 4,444,444 common shares at $22.50. The overallotment is 666,666 shares.
- The company expects it to close on or about March 26.
- Proceeds to fund general corporate purposes including R&D, expanding manufacturing capabilities, clinical trials and potential acquisitions.
Mar. 19, 2014, 4:39 PM
Mar. 19, 2014, 4:12 PM
Mar. 6, 2014, 12:52 PM
Mar. 6, 2014, 9:15 AM
- Gainers: PXLW +38%. BORN +30%. SGMO +17%. ERII +14%. BSPM +14%. ORAN +10%. BSDM +9%. GEVO +9%. LJPC +8%. ROX +8%. RIGL +8%. RGSE +8%. NEON +8%. PPHM +7%. NAVB +7%. FREE +6%. PSTI +6%. MVIS +5%. LOGI +5%. GRO +5%.
- Losers: LOV -20%. XGTI -13%. PLCE -12%. SPLS -11%. BLDP -8%. FCEL -6%. DANG -6%. MXWL -6%.
Mar. 6, 2014, 7:40 AM
- Sangamo BioSciences' (SGMO) first clinical study, a phase 1 trial conducted on six HIV-positive patients over 12 weeks, demonstrates that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. This could potentially be a way to control HIV infection without the use of drugs.
- In the study, T-cells from the subjects were isolated and edited with ZFNs to make them resistant to the HIV virus by knocking out the CCR5 gene that encodes a coreceptor required for infection. The altered cells, SB-728-T, were returned to the subjects via autologous infusion.
- The ZFN-modified cells showed preferential survival over unmodified cells and were able to persist and circulate throughout the body to key reservoirs of HIV infection such as gut-associated lymphoid tissue.
- Shares are up 14% in early trading.
Mar. 5, 2014, 6:32 PM
- Sangamo Biosciences (SGMO) +15.4% AH after announcing the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease-based genome editing technology in humans.
- SGMO says data from the study, carried out in HIV-positive subjects, shows the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection, demonstrating the feasibility of this genome editing approach to achieve functional control of HIV.
Feb. 11, 2014, 4:09 PM| Comment!
Feb. 11, 2014, 12:10 AM
Feb. 10, 2014, 5:35 PM
Jan. 9, 2014, 12:50 PM
SGMO vs. ETF Alternatives
Sangamo BioSciences Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development & commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.
Other News & PR